CZ751289A3 - Preparation for oral administration inhibiting formation of plaque - Google Patents

Abstract

Oral compsn contg. a water-insoluble non-cationic antibacterial agent (I) is packaged in a dispenser in which it is in contact with a solid polymeric material (A) which is compatible with (I) and does not cause excessive losses of (I) during storage. (A) is a synthetic organic plastic, esp. PTFE (best) or polyvinyl chloride). If the compsn includes a terpene or flavouring agent as stabiliser for (I), other polymers such as polyethylene, polypropylene, polymethyl pentene, polyallomers, nylon, polycarbonate and polysulphone can also be used.

Description

Technical field

The present invention relates to an anti-dental plaque composition for oral administration in the form of a gel-like or pasty dental cleaning composition, a liquid dental cleaning composition, a mouthwash, a lozenge or a chewing gum composition that is substantially free of tartar antiphosphate. These are non-cationic insoluble antibacterial agents capable of effectively preventing the formation of dental plaques.

BACKGROUND OF THE INVENTION

The dental coating is a soft deposit that forms on the teeth, as opposed to tartar, which is a hard calcified deposit. In contrast to tartar, the dental plaque can be formed on any part of the tooth surface, especially at the boundary between the tooth and the gum. This deposit, although not visible, is likely to promote tooth inflammation.

In view of the above, it is highly desirable to use antimicrobial agents to reduce dental plaque formation in oral dentifrices. US Pat. No. 4,022,880 (Vinson et al.) Discloses the use of a mixture of a zinc ion-releasing compound as an anti-tartar and an anti-bacterial active agent for this purpose. in inhibiting the growth of bacteria in the dental plaque. A variety of antibacterial agents are known in the art to be used in combination with these zinc compounds, including cationic agents such as guanides and quaternary ammonium compounds, as well as the use of non-wicking ionic agents such as halogenated salicylanilides and halogenated hydroxydiphenyl ethers. These non-cationic antibacterials such as halogenated hydroxy diphenyl ether, or triclosan, in combination with zinc citrate trihydrate are described in published European Patent Application No. 161,899 to Saxton et al. The use of this triclosan as a toothpaste component which additionally contained a solubilizing agent has also been described in European Patent Application Publication No. 0271 332 (Davis).

Recently, cationic antibacterials such as chlorhexidine, benzothonium chloride and cetylpyridinium chloride have also been of great interest as anti-dental antibacterial agents. However, these substances are usually not effective when used together with anionic materials. On the other hand, nonionic antibacterial agents are compatible with the anionic components in the oral compositions.

However, oral compositions usually comprise mixtures of many components and even such typical neutral substances such as solvents and respirators. humectants can affect the effectiveness of these compositions.

However, non-cationic antibacterial agents may also have limited dental plaque effectiveness when used in combination with some commonly used materials, such as polyphosphates, which are disclosed as tartar preventing agents in UK Patent Application Publication No. 2200551 Gaffar et al.) And European Patent 251591 (Jackson et al.). It is also known in the art that anti-dental efficacy can be substantially improved by adding a substance which promotes the action of an antibacterial agent (hereinafter referred to as AEA) to the composition, which improves the delivery of the antibacterial agent to the surface and, in addition, retention of the agent on the surface of the oral cavity, and a solution is also known to optimize the amount of polyphosphate and AEA in the oral composition.

SUMMARY OF THE INVENTION

According to the invention, it has been completely unexpected that by advantageously combining the various properties of the compounds, an oral formulation can be prepared in which a substantially water-insoluble non-cationic antibacterial and an AEA (antibacterial enhancing agent) compound are used to inhibit dental plaque formation. wherein the composition is a liquid vehicle for oral administration which allows effective dissolution of said antibacterial agent in the saliva in an amount that can effectively prevent the formation of a dental plaque.

The invention thus relates to an anti-dental plaque composition for oral administration in the form of a gel-like or pasty dentifrice, liquid dentifrice, mouthwash, lozenge or chewing gum substantially free of di. an anti-tartaric phosphate (pyrophosphate) agent, comprising a vehicle for oral administration and 0.01 to 5% by weight of a substantially water-insoluble non-cationic antibacterial agent dissolved in said vehicle in an effective amount to prevent dental plaque formation; characterized in that the vehicle also contains from about 0.005% to about 4% by weight of an antibacterial promoting agent having an average molecular weight of from about 100,000 to about 1,000,000 which comprises at least one acidic function with a release promoting agent to promote release of said antibacterial agent on tooth and gum surfaces in the oral cavity and at least one organic group of the formula:

—O (x) _n - ^R in which:

X represents oxygen, nitrogen, sulfur, SO, S0 _2, P, PO or Si,

R is a hydrophobic alkyl group, an alkylene group, an acyl group, an aryl group, an alkaryl group, and an aralkyl group containing from 1 to 12 carbon atoms, or an inert substituted derivative thereof, and n is 1 or zero, with retention aid for promoting retention of said antibacterial tooth and gum surface agents in the oral cavity, wherein the AEA comprises natural and synthetic polymerizable monomers, oligomers, homopolymers, copolymers consisting of two or more monomers, ionomers, block copolymers, graft copolymers or crosslinked copolymers or monomers containing styrene phosphonic acid polymers, phosphonated polymerized ethylenically unsaturated compounds, polymerized ethylenically unsaturated carboxylic acids, carboxyvinyl polymers, polysiloxanes, polyesters, polyurethanes, natural or synthetic polyamides,

Preferably, the composition for oral administration further optionally comprises solubilizing agents and / or polishing agents. The solvent is present in an amount ranging from 0.5 to 50% by weight, selected from the group consisting of propylene glycol, dipropylene glycol, hexylene glycol, methylcellosol, ethylcellosol. vegetable oils and waxes containing at least 12 carbon atoms, amyl acetate, ethyl acetate, glyceryl tristearate and benzyl benzoate. The dissolving agent may comprise propylene glycol which is present in an amount of 0.5% by weight.

According to a preferred embodiment, the composition of the invention is in the form of a dentifrice and comprises 5 to 30% by weight of a silica or aluminate polishing agent and said antibacterial agent is present in an amount ranging from 0.25 to 0.35% wherein a surfactant and a flavoring oil are further present.

According to a further preferred embodiment, the composition is in the form of a dentifrice and comprises 5 to 30% by weight of a silica or aluminum silicate polishing composition, said antibacterial agent is present in an amount of from 0.01 to 5% by weight, and the oral composition comprising administering a solvent to dissolve said antibacterial agent in the saliva.

Said antibacterial agent is preferably present in an amount from 0.05% to 0.25% by weight, more preferably from 0.35% to 5% by weight, and most preferably from 0.35% to 0.5% % by weight.

This composition for oral administration is preferably in the form of a cream dentifrice composition containing 30 to 75% by weight of a water-insoluble dentifrice.

According to another preferred embodiment, the composition is in the form of a mouthwash or a liquid dentifrice, and said orally acceptable vehicle is an aqueous vehicle comprising at least one surfactant, flavoring oil or non-toxic alcohol. The surfactant is preferably present in an amount ranging from 0.5 to 5% by weight and the flavoring oil in an amount ranging from 0.1 to 5% by weight,

Said composition is preferably in the form of a mouthwash and said aqueous vehicle comprises ethanol and the weight ratio of water to ethanol ranges from 1: 1 to 20: 1.

The composition according to the invention is preferably in the form of a liquid dentifrice composition containing 0.3 to 2.0% by weight of a high molecular weight polysaccharide of greater than 1,000,000 containing mannose, glucose, potassium glucuronate and acetyl groups in a ratio of:

2: 1: 1: 1 as a suspending and thickening agent and 10 to 20% by weight of a polishing agent.

Said antibacterial agent may be selected from the group consisting of halogenated diphenyl ethers, halogenated salicylanides, benzoic acid esters, halogenated carbanilides and phenolic compounds. Preferably, said antibacterial agent is halogenated diphenyl ether, most preferably said halogenated diphenyl ether is 2,4,4'-trichloro-2'-hydroxyphenyl ether,

The polishing agent used may be selected from the group consisting of sodium metaphosphate, calcium phosphate, dibasic calcium phosphate dihydrate, anhydrous dibasic calcium phosphate, pyrophosphate (pyrophosphate), magnesium orthophosphate, magnesium phosphate, calcium carbonate, aluminum silicate, aluminum silicate, aluminum silicate, silicate mixtures thereof, and the composition for oral administration is in the form of a cream dentifrice, preferably the polishing agent is dibasic calcium phosphate dihydrate or hydrated alumina.

Said release-promoting group is preferably selected from the group consisting of carboxylic acids, phosphonic acids, phosphinic acids and sulfonic acids and salts thereof, and mixtures thereof.

The antibacterial promoting agent is preferably an anionic polymer comprising a number of release-promoting and retention-promoting groups. The anionic polymer preferably comprises a chain comprising repeating units with at least one carbon atom. Each unit preferably comprises at least one release promoting group attached to the same atom, an adjacent atom, or to another atom in the chain.

Most preferably, said antibacterial enhancer is a copolymer of maleic acid or anhydride thereof with another inert ethylenically unsaturated polymerizable monomer. Preferably, the second monomer of the copolymer is methyl vinyl ether, in a molar ratio ranging from 4: 1 to 1: 4 based on the amount of maleic acid or anhydride thereof. The copolymer preferably has a molecular weight ranging from 30,000 to 1,000,000, and is present in an amount ranging from 0.1 to 2% by weight, most preferably having an average molecular weight of 70,000.

Specifically, the antibacterial enhancer may be a polymer of poles (beta-styrene phosphonic acid) or poles (alpha-styrene phosphonic acid), or a copolymer of any of said styrene phosphonic acids with another ethylenically unsaturated monomer.

In a particular preferred embodiment, the composition for said antibacterial promoting agent has an average molecular weight ranging from 1,000 to 1,000,000 and is substantially free of water-soluble, alkali metal or ammonia-containing, linear anionic linear polymeric polycarboxylates. between 1,000 and 1,000,000, wherein the antibacterial agent is present in an amount ranging from 0.25% to 0.5% by weight, most preferably in an amount ranging from 0.25% to 0.35% by weight.

Furthermore, the composition preferably comprises a polishing agent based on silicon dioxide or aluminum silicate.

A great advantage of the composition according to the invention is that AEA favorably affects both the delivery and retention of a small but anti-dental plaque effective amount of an antibacterial, both on the teeth and on the soft tissues occurring in the oral cavity.

A further advantage of the present invention is that a composition is provided that reduces the incidence of gingivitis.

Typical examples of non-cationic non-cationic, water-insoluble antibacterials are particularly useful in terms of dental plaque suppression, effectiveness, safety in use and ease of formulation.

Halogenated diphenyl ethers

2 ', 4,4'-trichloro-2-hydroxydiphene ether (triclosan),

2,2´-dihydroxy-5,5'-dibromodiphenyl ether,

Halogenated salicylanilides

4 ', 5-dibromsaiicylani people,

3,4 ’, 5-1richlorsalicylani people,

3,4 ’, 5-tribromsalicylani people,

2,3,3 ’, 5-tet rachlorsalicylan.il id,

3,3,3 ', 5-tetrachlorosalicyllanilide,

3,5-dibromo-3´-trilluoromethylsalicylanilide,

5-n-ok tanoy1-3'-t rifluoromethylsalicylanilide

3,5-dibromo-4'-trifluoromethylsalicylanilide,

3,5-dibromo-3'-trifluoromethylsalicylanilide (fluorophene).

Benzoic acid esters methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate.

- βο p-hydroxybenzoic acid propyl ester and p-hydroxybenzoic acid butyl ester,

Halogenated carbanilides 3,4,4'-trichlorocarbans,

3-Trifluoromethyl-4,4'-dichlorocarbanilide

3,3,4’-trichlorocarbanilide.

Phenol compounds (including phenol and its homologues, mono- and polyalkylated and aromatic halogenated, i.e., fluorinated, chlorinated, brominated and iodinated, phenols, resorcinol and catechol and derivatives thereof and bisphenolic compounds): phenol,

2-Methylphenol

3-methyl phenol,

4-Methylphenol

4-ethylphenol,

2,4-Dimethylphenol

2.5-dimethylphenol,

3,4-dimethylphenol,

2,6-dimethylphenol,

4-n-propylphenol,

4-n-Butylphenol

4-n-amylphenol,

4-tert-amylphenol,

4-n-hexylphenol,

4-n-heptylphenol,

2-methoxy-4- (2-propenyl) phenol (eugenol),

2-isopropyl-5-methylphenol (thymol).

Mono- and polyalkyl- and arylalkyl-halophenols methyl-p-chlorophenol, ethyl-p-chlorophenol, n-propyl-p-chlorophenol, n-butyl-p-chlorophenol, n-ainyl-p-chlorophenol, sec-amyl-p-chlorophenol , n-hexyl-p-chlorophenol, cyclohexyl-p-chlorophenol, n-heptyl-p-chlorophenol, n-octyl-p-chlorophenol, o-chlorophenol, methyl-o-chlorophenol, ethyl-o-chlorophenol, n-propyl -o-chlorophenol, n-butyl-o-chlorophenol, n-amyl-o-chlorophenol, tert-amyl-o-chlorophenol, n-hexyl-o-chlorophenol, n-heptyl-o-chlorophenol, p-chlorophenol, o-benzyl-p-chlorophenol, o-benzyl-m-methyl-p-chlorophenol, o-benzyl-m, md imethyl-p-chlorophenol, o-phenylethyl-p-chlorophenol, o-phenylethyl-m-methyl- p-chlorophenol,

3-methyl-p-chlorophenol,

3,5-Dimethyl-p-chlorophenol

6-ethyl-3-methyl-p-chlorophenol,

6-n-propyl-3-methyl-p-chlorophenol,

6-isopropyl-3-methyl-p-chlorophenol, 2-ethyl-3,5-dimethyl-p-chlorophenol,

6-sec-butyl-3-methyl-p-chlorophenol,

2-Isopropyl-3,5-dimethyl-p-chlorophenol 6-diethylmethyl-3-methyl-p-chlorophenol

12-6-isopropyl-2-ethyl-3-methyl-p-chlorophenol 2-sec-3,5-dimethyl-p-chlorophenol, 2-diethylmethyl-3,5-dimethyl-p-chlorophenol 6-sec. octyl-3-methyl-p-chlorophenol, p-bromophenol, methyl-p-bromophenol, ethyl-p-bromophenol, n-propyl-p-bromophenol, n-butyl-p-bromophenol, n-amyl-p-bromophenol, sec-amyl-p-bromophenol, n-hexyl-p-bromophenol, cyclohexyl-p-bromophenol, o-bromophenol, tert-amyl-o-bromophenol, n-hexyl-o-bromophenol, n-propyl-m, m- dimethyl-o-bromophenol,

2-phenylphenol,

4-chloro-2-methylphenol,

4-chloro-3-methylphenol,

4-chloro-3,5-dimethylphenol,

2,4-chloro-3,5-dimethyl, phenol,

3,4,5,6-tetrabromo-2-methylphenol,

5-methyl-2-pentylphenol,

4-Isopropyl-3-methylphenol

5-chloro-2-hydroxydiphenylmethane.

Resorcinol and its derivatives resorcinol, methylresorcinol, ethylresorcinol, n-propylresorcinol, n-butylresorcinol, n-amylresorcinol, n-hexylresorcinol, n-heptyresorcinol, n-ocrylresorcinol, n-nonylresorcinol, phenylresorcinol, phenyresorcinol, benzylresorcinol, benzylresorcinol, benzylresorcinol

5-chloro-2,4-dihydroxydiphenylmethane,

4´-chloro-2,4-dihydroxyd ifenylmethane,

5-bromo-2,4-dihydroxydiphenylmethane, ´-bromo-2,4-dihydroxydiophenylmethane.

Biphenol compounds bisphenol A,

2,2'-methylenebis (4-chlorophenol),

2,2'-methylenebis (3,4,6-trichlorophenol) (hexachlorophene),

2,2´-methylenebis (4-chloro-6-bromophenol), bis (2-hydroxy-3,5-dichlorophenyl) sulfide, bis (2-hydroxy-5-chlorobenzyl) sulfide.

The non-cationic antibacterial is present in the oral composition according to the invention in an amount effective against dental plaque formation, usually in an amount ranging from 0.01% to 5% by weight, in particular 0.03% to 1%. % by weight, preferably from 0.25% to 0.5% by weight, and most preferably from 0.25% to 0.5% by weight, most preferably from 0.25% to 0.35% by weight, for example 0.3 or 0.03% to 0.3% by weight, in particular 0.03% to 0.1% by weight, of a composition used as a mouthwash or as a liquid dentifrice. The antibacterial agent should be substantially insoluble in water, which means that its solubility in water should be less than about 1% by weight at 25 ° C, but may be less than 0.1% by weight.

Of the halogenated diphenyl ethers, the preferred compound is triclosan. Among the phenolic compounds, phenol, thymol, eugenol, hexylresorol and 2,2 ' -methylene-bis (4-chloro-6-bromophenol) are particularly preferred. However, the most preferred anti-tartaric antibacterial agent is triclosan. This triclosan is described in the aforementioned U.S. Patent No. 4,022,880 as an antibacterial agent, which can be used in combination with a tartaric agent that provides zinc ions. In addition, triclosan is also disclosed in DE 3,532,860 as a substance which can be combined with compounds containing copper. European Patent 278,744 discloses the use of triclosan in combination with substances that desensitize teeth and contain a source of potassium ions. Triclosan is also referred to as a dentifrice in a dentifrice composition which comprises a lamellar liquid crystal surfactant in which the spacing between individual lamellae is less than 6.0 nm, which composition may also contain zinc salt, this composition is described in European Patent 161 988 (Lané et al.). Triclosan has also been used in a dentifrice composition containing zinc citrate trihydrate as described in European Patent No. 161,899 (Saxton et al.).

The antibacterial agent (AEA), which improves the delivery and retention of the agent to the surface of the oral cavity, is used in an amount sufficient to achieve this effect, which is typically an amount ranging from 0.05% to 4% by weight. % by weight, preferably from 0.1% to 3% by weight, in particular from 0.5% to 2.5% by weight.

The AEA may be a simple compound, preferably a polymerizable monomer, even more preferably a polymer, and the term is quite general and includes, for example, oligomers, homopolymers, copolymers of two or more monomers ionomers, block copolymers, graft copolymers, crosslinked polymers and copolymers, and similar other substances. The AEA may be of natural or synthetic origin, may be water insoluble or preferably water soluble (i.e., saliva), or may be swellable (hydratable, forming a hydrogel). The molecular weight of these substances can generally be in the range from 100 to 1,000,000, preferably from 1,000 to 1,000,000, particularly preferably in the range of 2,000 or 2,500 to 250,000 or 500,000.

These AEAs usually contain at least one group to aid in the delivery of an active agent that is acidic in nature, such as a sulfonic acid, phosphoric acid or, preferably, phosphonic or carboxylic acid residue, or a salt thereof, such as an alkali metal salt; an ammonium salt, and at least one organic moiety promoting retention (or retention) of the active agent on the mucosal surface, preferably comprising a plurality of both types of the above groups. These retention-promoting groups can be represented by the general formula;

- <x> _n - ^R in which;

X is oxygen, nitrogen, sulfur, SO, SO ₂ , phosphorus, PO or Si, and the like,

R represents a hydrophobic alkyl, alkenyl, acyl, aryl, alkaryl, heterocyclic or inertly substituted derivatives thereof, and n is 0, 1 or higher.

By the term "inertly substituted derivatives" is meant substituents on the R group, which are generally non-hydrophilic and which do not substantially affect the desired AEA function in promoting delivery of the antibacterial agent to the oral mucosal surface and retention of the agent on the oral mucosal surface. and wherein the inertly substituted derivative may be a halogen substituted group such as chlorine, bromine, iodine, or a carbocycle and the like.

Examples of these groups promoting the delivery of the antibacterial agent to the oral cavity surface and its retention on the oral cavity surface will be reviewed below.

η X - (X) _n ^R

Ο - methyl, ethyl, propyl, butyl, isobutyl, tert-butyl, cyclohexyl, allyl, benzyl, phenyl, chlorophenyl, xylyl, pyridyl, furanyl, acetyl, benzoyl a group, a butyryl group, a terephthaloyl group, etc.

0 ethoxy, benzyloxy, thioacetoxy, phenoxy, carbethoxy, carbobenzyloxy, etc.

Ethylamino, diethylamino, propvoyl, benzylamino, benzoylamino, phenylacetamide, etc.

S thiobutyl, thioisobutyl, thioallyl, thiobenzyl, thiophenyl, thiopropionyl, phenylthioacetyl, thiobenzoyl, etc.

SO butylsulfoxy, allylsulfoxy, benzylsulfoxy, phenylsulfoxy, etc.

lft

η X -W _n R i so ₂ butylsulfonyl, allylsulfonyl, benzylsulfonyl, phenylsulfonyl, etc. P diethylphosphinyl, ethylvinyl- phosphinyl, ethylallylphosphinyl, ethylbenzylphosphinyl, ethylphenylphosphinyl, etc. AFTER diethylphosphinoxy, ethylvinylphosphinoxy, methylallylphosphinoxy, methylbenzylphosphinoxy, methylphenylphosphinoxy, etc. Si trimethylsilyl, dimethylbutylsilyl, benzylsilyl, dimethylvinylsilyl, dimethylallylsilyl group, etc.

When used in an oral formulation, the group promoting the delivery of the antibacterial agent to the oral cavity surface, i.e., the tooth and gum surfaces, is a substance that associates by adhesion, cohesion or otherwise with AEA (containing the antibacterial agent) this surface. The organic group that promotes retention of the antibacterial agent on this surface is generally a hydrophobic group that binds or otherwise attaches the antibacterial agents to the AEA, thereby promoting the retention of the antibacterial agent to the AEA and thus indirectly on the oral cavity surface. In some cases, the capture of the antibacterial agent is achieved by physically attaching the agent to the AEA, particularly when the AEA is a crosslinked polymer, the structure of which itself increases the number of sites for binding or binding. connection. The presence of the higher molecular weight moiety and the presence of multiple moieties with hydrophobic crosslinked moieties in the crosslinked polymer further enhance the possibility of physically entrapping the antibacterial agent onto or across the crosslinked AEA polymer.

Preferably, the AEA is an anionic polymer consisting of a chain or backbone containing repeating units, each containing at least one carbon atom and preferably at least one directly bound or indirectly attached pendant monovalent group to promote the delivery of the active antibacterial agent and at least one directly or indirectly coupled monovalent monovalent moiety promoting retention of the active antibacterial agent, namely geminally, vicinally or less preferably by other means to atoms in the chain, preferably carbon atoms. It is less preferred that the polymer contains antibacterial agent delivery support groups and / or antibacterial agent retention groups and / or other divalent atoms or groups as linkers in the polymer chain instead of or in addition to the carbon atoms as crosslinkers.

It is contemplated that any examples of AEAs herein that do not contain both antibacterial agent and retention groups may be, and preferably are chemically modified in such a way that such types of AEAs are obtained, In the case of preferred polymeric AEAs, it is desirable, in order to maximize the effect and encourage the delivery of the antibacterial agent to the oral cavity surface, to have repeating units in the polymer chain or polymer backbone. containing acidic groups promoting antibacterial agent delivery comprise at least about 10% by weight of the polymer, preferably at least about 50% by weight, even more preferably at least about 80% by weight up to about 95% or even 100% by weight of the polymer.

Preferably, the AEA comprises a polymer comprising repeating units in which one or more phosphonic acid groups supporting the delivery of the antibacterial agent is bound to one or more carbon atoms in the polymer molecule. An example of these AEAs are (vinyl phosphonic acid) polyesters containing units of formula Γ:

- [CIL, —CH] -

I (i)

P ° 3 ^H2

However, this group does not contain a group which promotes retention of the antibacterial agent on the surface of the oral cavity. However, a group of this type is present in the poles (1-phosphonpropene) having the formula II:

- [CH — CH] -

II (II) ch ₃ after ₃ h ₂

A preferred type of AEA containing phosphonic acid for use according to the invention is the (β-styrenephosphonic) poly (III) acid:

- [CH — CH] -

I (I)

Fh PO ₃ H ₂ wherein Ph is a phenyl group, the phosphonic acid-promoting and antibacterial retention-promoting phosphonic acid groups are bonded to vicinal carbon atoms in the chain, or a β-styrene-phosphonic acid-vinyl-1-phosphonyl chloride copolymer having units of formula ΙΓΙ s units of formula I, see above in alternating or statistical order, or poly (α-styrene phosphonic) acid containing units of formula IV;

Ph (IV) after ₃ h ₂ wherein both the feeder and the retention groups of the antibacterial are bonded to the same carbon atom in the chain.

These styrene phosphonic polymers and copolymers thereof with other inert, ethylenically unsaturated monomers have, as mentioned above, a molecular weight in the range of from 2000 to 30,000, preferably in the range of from 2500 to 10,000. the monomers do not adversely affect the intended function of any polymer used in the AEA of the invention.

Other phosphonic acid-containing polymers include, for example, phosphonated ethylene compounds having units of formula V;

- ((CH ₂ ) ₁₄ chpo ₃ h ₂ ] _n - (V) wherein n can be, for example, an integer such that the polymer of formula V has a molecular weight of about 3000, and sodium salt poles (butene-4,4) -diphosphonate) with units of formula VI:

- [CH ₂ -CH ₂ ] -

I (VI)

CH ₂ -CH <(PO ₃ Na ₂ ) ₂ and poles (allyl-bis (phosphonethylamine)) with units of formula VII:

- [CH ₂ -CH ₂ ] -

I (VII)

CH ₂ -N? (PO ₃ H ₂ ) ₂

Other phosphonated polymers such as poles (allylphosphonacetate), phosphonated polymethacrylate, etc., as well as the geminal diphosphonate polymers disclosed in European Patent No. 321233, can be used as AEAs, provided they contain both types of the above groups or are modified in such a way as to include these two types.

In one aspect, the oral composition comprises an orally acceptable vehicle, an effective amount of a substantially water-insoluble non-cationic antibacterial agent in an effective amount against dental plaque formation, and an antibacterial promoting agent having an average molecular weight ranging from about 1,000 to about 1 000 000, comprises at least one functional group promoting the delivery or release of an antibacterial agent and at least one organic group having a retention aid (retention promoting group), said agent not containing or substantially free of a water-soluble synthetic anionic polycarboxylate salt of a linear alkali metal polymer; an ammonium salt having a molecular weight ranging from about 1,000 to about 1,000,000.

According to another preferred embodiment, the AEA may comprise one of the synthetic anionic polymeric polycarboxylates. Γ when the following compounds are not used to interact with polyphosphate agents as anti-tartar agents, it should be noted that synthetic anionic polymeric polycarboxylates have a molecular weight of about 1000 to 1,000,000, preferably ranges from about 30,000 to 500,000 are used as alkaline phosphatase enzyme inhibitors in optimizing the effectiveness of linear molecular dehydrated polyphosphates against calculus formation, such as disclosed in U.S. Patent 4,627,977 (Gaffar et al.). United Kingdom published patent application No. 22,00551 describes polymeric polycarboxylates as an optional component of oral compositions comprising linear molecularly dehydrated polyphosphate salts and substantially water-insoluble non-cationic antibacterial agents. In addition, it has been found in connection with the present invention that the polycarboxylate is considerably more effective with respect to the delivery and retention of a nonionic antibacterial agent effective against dental plaque formation on the tooth surface even when no other co-acting component is present with said polymeric polycarboxylate (i.e., molecularly dehydrated polyphosphate), for example when the component that interacts with the polymeric polycarboxylate is in particular a non-cationic antibacterial agent.

Synthetic anionic polymeric polycarboxylates and their complexes with various cationic disinfectants, zinc and magnesium are known in the art as anti-tartar agents per se, for example U.S. Patents 3,429,963 (Shedlovsky), 4 152,420 (Gaffar et al.), 3,956,480 (Dichter et al.), 4,138,477 (Gaffar et al.) And 4,183,914 (Gaffar et al.). It should be noted, however, that the synthetic anionic polymeric polycarboxylates mentioned in these several patents, when they contain or are modified by the retention-promoting groups as defined above, are active substances which can thus be used in the oral compositions and processes of the invention. These publications are reference materials in the context of the present invention.

The synthetic anionic polymeric polycarboxylates used in the present invention are well known in the art, which are often used in the form of the free acids or preferably in the form of partially neutralized salts or even more preferably in the form of completely neutralized salts which are water-soluble. or water-swellable (hydratable form, gel-forming form), preferably being an alkali salt (such as a potassium salt or preferably a sodium salt) or ammonium salts. Preference is given to using copolymers of maleic anhydride or maleic acid with another polymerizable ethylenically unsaturated monomer in a ratio of 1: 4 to 4: 1, preferably a methyl vinyl ether / maleic anhydride copolymer having a molecular weight in the range of from 1: 4 to 4: 1. about 30,000 to about 1,000,000, preferably in the range of about 30,000 to about 500,000. These copolymers are available under the designation Gantrez, such as AN 139 (500,000 molecular weight), AN 119 (250,000 molecular weight), and preferably S-97 of pharmaceutical grade (molecular weight 70,000), manufactured by GAF Corporation.

Among other AEA active polymeric polycarboxylates. which contain or are modified by retention-enhancing groups may include, for example, those disclosed in U.S. Pat.

956,480 mentioned above, in particular copolymers of maleic anhydride with ethyl acrylate in a ratio of 1: 1, furthermore hydroxyethyl methacrylate,

26 N-vinyl-2-pyrrolidone or ethylene, the latter being, for example, commercially available Monsanto EMA No. 1103 having a molecular weight of 10,000 and EMA Grade 61, and copolymers of acrylic acid with methyl or hydroxyethyl methacrylate, methyl or ethyl acrylate, isobutyl vinyl ether or N-vinyl-2-pyrrolidone in a 1: 1 ratio.

Other effective polymeric polycarboxylates include, for example, copolymers of maleic anhydride with styrene, isobutylene or ethyl vinyl ether, noracrylic acid polymers, polyitaconic acid and polymaleic acid oligomers, and sulfoacrylic oligomers having a molecular weight of about 1000, cited in U.S. Pat. .

138 477 and 4,183,914 and commercially available, for example, Uniroyal ND-2, which contain or are modified by antibacterial retention-promoting groups.

In general, retention-promoting groups which contain polymerizable olefinically or ethylenically unsaturated carboxylic acids containing an activated olefinic carbon-carbon double bond that is readily functional during polymerization due to its presence in the monomeric molecule either in the monomer molecule are suitable for the purposes of the present invention. position α-β relative to the position of the carboxyl group or as part of the terminal methylene group. Examples of such acids are acrylic acid, methacrylic acid, ethacrylic acid, α-chloroacrylic acid, crotonic acid, β-acryloxypropionic acid, sorbic acid, α-chlorosorbic acid, cinnamic acid, β-styrylacrylic acid, muconic acid. , citraconic acid, mesaconic acid, glutaconic acid, aconitic acid, α-phenylacrylic acid, 2-benzylacrylic acid, 2-cyclohexylacrylic acid, angelic acid, umbelic acid, fumaric acid, maleic acid and anhydrides thereof. Other different olefinic monomers copolymerizable with said carboxyl monomers include vinyl acetate, vinyl chloride, dimethyl maleate and the like. The copolymers usually contain a sufficient number of carboxylic acid salt groups to achieve water solubility of the carboxylic acid.

The so-called carboxyvinyl polymers, referred to as toothpaste components in U.S. Patent Nos. 3,980,767 (Chown et al.), 3,935,306 (Roberts et al.), Are also useful for the above purposes.

919,409 (Perla et al.), 3,911,904 (Harrison), and 3,711,604 (Colodney et al.). These materials are commonly marketed under the tradenames Carbopol 934, 940 and 941 by B.F. Goodrich, wherein the products consist essentially of a colloidal water-soluble polyacrylic acid polymer crosslinked by the addition of 0.75% to about 2.0% polyallylsaccharose or polyallylpentaerythritol as crosslinking agent, wherein the crosslinked structures and crosslinking bonds provide the desired retention enhancement due to the hydrophobic nature such structures and / or due to physical entrapment of the antibacterial agent and the like. Polycarbophil is a similar substance, being a polyacrylic acid cross-linked with less than 0.2% divinyl glycol, with the lower proportion, molecular weight and / or hydrophobicity of the cross-linking agent providing little or no improvement in retention. In contrast, 2,5-dimethyl-1,5hexadiene, for example, is a more effective cross-linking agent that promotes retention of the antibacterial agent.

The synthetic anionic polymeric polycarboxylate component is most often a hydrocarbon-type component with optionally present halogen and substituents with an O-bond and with bonds present, for example, in ester, ether and OH groups, and is present in the compositions of the present invention in an approximate 05% to 4% by weight, preferably from 0.05% to 3% by weight, most preferably from 0.1% to 2% by weight.

The AEA may also comprise natural anionic polymeric polycarboxylates containing retention groups of the antibacterial agent. Carboxymethylcellulose and other binding and film-forming agents which do not contain the above-mentioned antibacterial agent-promoting groups and / or retention-promoting groups of the antibacterial agent are ineffective as AEAs.

Illustrative examples of AEAs containing phosphinic acid and / or sulfonic acid groups that promote the delivery of an antibacterial agent include polymers and copolymers containing units or moieties derived from the polymerization of vinylphosphonic or allylphosphonic acid and / or sulfonic acid substituted as needed on one or two (or three) carbon atoms by organic retention promoting groups, such as the groups of the above formula - (X) _n -R as defined above. Mixtures of these monomers and copolymers of these with one or more may also be used

inert polymerizable ethylenically unsaturated monomers, such as those mentioned above in connection with active synthetic anionic polymeric polycarboxylates. As will be noted, in these agents and in other polymeric AEA agents suitable for the purpose of the present invention, usually only one acid group promoting the antibacterial agent is attached to any carbon atom or other atom in the polymer backbone or to the branching of this backbone . It is also possible to use polysiloxanes containing pendant groups to promote the delivery of the antibacterial agent and the retention of or modified to contain these groups as AEAs. Also useful as AEAs are ionomers containing said groups to promote the delivery of the antibacterial agent and the retention of the antibacterial agent or modified to contain these groups. These ionomeric materials are described in Kirk Othmer Encyclopedia of Chemical Technology, Third Edition, Supplement Volume, John Wiley & Sons, Inc. copyright, 1984, pp. 546-573, the disclosure of which is incorporated herein by reference. Also useful as AEAs are polyesters, polyurethanes, and synthetic and natural polyamides, including proteins and protein materials such as collagen, poles (arginine) and other polymerizable amino acids, if they contain or have been modified to contain retention-promoting groups.

According to one aspect of the present invention, an AEA having an average molecular weight of 1,000 to 1,000,000 comprises at least one functional group with a sustained release effect and at least one organic group with a sustained release effect, said substance being free of or substantially free of water soluble

- a 3U synthetic anionic linear polymeric polycarboxylate salt with an alkali metal or ammonium salt having a molecular weight of 1 000 to 1 000 000.

A dentifrice composition containing about 0.3% by weight of an antibacterial (e.g., triclosan) and about 1.5 to 2% by weight of a polycarboxylate such as AEA is particularly suitable for oral use.

Without wishing to be bound by theory, it is likely that AEA, especially polymeric AEA, is generally an anionic film-forming material, and it is believed that the film-forming material binds to the tooth surface and forms a continuous film on the surface thereby preventing access. bacteria to the tooth surface. It is possible that the non-cationic antibacterial agent forms a complex or other form of association with the AEA, thereby forming a film of the complex or other form of association with the AEA on the tooth surface.

The film-forming property of the AEA and the promoting and releasing effect and retention of the antibacterial on the tooth surface due to the effect of the AEA apparently causes the tooth surface to become an unfavorable area for bacterial settling and accumulation, since the direct bacteriostats inhibits bacterial growth. Therefore, three types of effect are combined:

1) stimulating release effect,

2) prolonged retention time on the tooth surface, and

3) preventing bacteria from adhering to the tooth surface, thereby effectively preventing the formation of dental plaque. A similar effect can be achieved on the soft tissues of the oral cavity near and at the edge of the gums.

According to the invention, an orally acceptable vehicle allows effective dissolution of a substantially water-insoluble non-cationic antibacterial in an effective amount to prevent plaque formation in the saliva.

In an oral composition, the vehicle used comprises an aqueous phase with an added solvent. In a dentifrice gel composition which typically contains from about 5% to about 30% by weight of a silica polishing composition, water is typically present in an amount of from about 3% to about 35% by weight of the solvent, preferably glycerol and / or sorbitol. 5% to 75% by weight or up to 80% by weight, based on the weight of the oral gel dentifrice. If sorbitol has been mentioned, it is a material which is commercially available in the form of a 70% aqueous solution.

Gel dentifrices do not require an additional ingredient for solubilizing the antibacterial when the antibacterial content is 0.25% to 0.35% by weight, although such ingredient may optionally be added to the present invention. If the amount of the antibacterial agent is less than 0.25% by weight, for example 0.01% to about 0.25% by weight, it is suitable to use a solubilizing agent to ensure sufficient saliva dissolution to achieve the desired efficacy against dental formation. coating. If the antibacterial is present in an amount greater than 0.35% by weight, for example 0.35% to 0.5% by weight or even more, a solubilizing agent is also required, as otherwise the bulk of the antibacterial agents in the undissolved state.

- J Z *

If the composition for oral administration is a cleaning composition containing from 30% to 75% by weight of the polishing composition, a solubilizing agent may also optionally be added.

When the oral composition is a mouthwash or a liquid dentifrice, the oral vehicle comprises at least one surfactant, a flavoring oil or a non-toxic alcohol, each of which helps to dissolve the antibacterial so that the presence of the solubilizing agent is only possible and not necessary.

When the oral composition contains a solubilizing agent, the amount is usually in the range of 0.5% to 20% by weight. An amount of 0.5% by weight is usually sufficient when the amount of the substantially water-insoluble non-cationic antibacterial is low, for example up to 0.3% by weight. If a higher amount of antibacterial agent is used, for example at least 0.5% by weight, and in particular when the silica polishing agent is present in an amount of 5% to 30% by weight, it is desirable to use at least 5% by weight, usually up to 20%. or even more percent by weight of the solubilizing agent. If the amount of solubilizing agent is greater than 5% by weight, the composition may tend to separate into a solid and a liquid fraction.

The agent intended to aid in the dissolution of the antibacterial agent in the saliva may be contained in a vehicle containing water as a humectant. Such solubilizing or wetting agents (or also moisture stabilizers) are, for example, polyols such as propylene glycol, dipropylene glycol and hexylene glycol, methylcellosolv, ethylcellosolv, vegetable oils and waxes containing at least 12 carbon atoms in a straight chain such as olive oil, castor oil, petrolatum, and petrolatum. esters such as amyl acetate, ethyl acetate and benzyl benzoate may be used. Propylene glycol means 1,2-propylene glycol and 1,3-propylene glycol. Larger amounts of polyethylene glycol, especially having a molecular weight of 600 or higher, should not be used because polyethylene glycol effectively reduces the antibacterial action of a non-cationic antibacterial. For example, when polyethylene glycol (PEG) 600 is included with triclosan in a weight ratio of triclosan: PEG 600 of 25: 1, the antibacterial activity of triclosan decreases sixteen times compared to that in the absence of PEG.

The dentifrice for oral administration may, according to one aspect of the present invention, be a gel, for example a gel dentifrice. The composition may comprise a silica polishing material, preferably a crystalline silica material having a particle size of up to 5 µm, an average particle size of up to 1.1 µm, and a specific surface area of up to about 50,000 cm / gram, which may be silica gel or colloidal silica and a complex amorphous alkali metal aluminosilicate.

When a clear or opaque gel is used, it is particularly suitable to use colloidal silica such as those sold under the names Syloid 72 and Syloid 74 or Santocel 100 or they may be alkali metal aluminosilicates (i.e. silica containing alumina incorporated in in their matrix), since these materials meet the needs for achieving a gel-like structure and have a refractive index close to that of liquid gelling agent systems (including water and / or wetting or dissolving agents) commonly used in dentifrices.

The polishing material is typically present in such compositions, such as toothpastes or gel formulations, in the range of about 5% to about 30% by weight.

In one aspect of the present invention, where the oral composition is in the form of a dentifrice, it typically comprises an orally acceptable vehicle comprising an aqueous phase with a humectant (or solvent or moisture stabilizer), preferably glycerol and / or sorbitol, water being present. usually in an amount ranging from about 15% to about 35%, or up to about 40% by weight, and glycerol and / or sorbitol is usually present in a total amount ranging from 20% to about 75% by weight, preferably from about 25% by weight to about 60% by weight. In the case of sorbitol, it is again a commercially available material in the form of 70% aqueous solution.

The oral dentifrice composition of the present invention may be substantially pasty in nature and thus may be a toothpaste, although in the presence of a silica polishing agent (which is not common since such material is typically not used in an amount greater than 30% by weight) have the nature of a gel. The vehicle for this oral dentifrice comprises a dentally acceptable polishing material, such as water insoluble sodium or potassium metaphosphate, calcium phosphate, calcium dihydrogen phosphate, anhydrous calcium phosphate, calcium carbonate, aluminum silicate, hydrated alumina, silica, bentonite and mixtures thereof or mixtures thereof with harder polishing materials, for example, calcined alumina and zirconium silicate, including the resins described in U.S. Patent 3,070,510 December 15, 1962, such as melamine-, phenola-urea-formaldehyde resins and cross-linked polyepoxides and polyesters. Insoluble aluminum metaphosphate is also a preferred polishing material.

Many of the so-called water-insoluble polishing materials are anionic in nature and, moreover, contain a small amount of soluble material. Insoluble sodium metaphosphate can be obtained by any suitable method, for example according to: Thorpe's Dictionary of Applied Chemistry, Vol. 9, 4th Edition, pp. 510-511. Another example of suitable materials are some forms of insoluble sodium metaphosphate, known as Madrell's salt and Kurrol's salt. These salts have only a low solubility in water, so they are usually referred to as insoluble metaphosphates (IMP). Small amounts of soluble phosphate material are usually present as impurities, usually up to 4% by weight. The amount of soluble phosphate, which includes probably soluble sodium trimetaphosphate, can be reduced or removed if necessary by washing with water. Insoluble alkali metal metaphosphates are usually used in the form of powders, the particle size of which is such that only a maximum of 1% of the material has particles larger than 37 gm.

υ

An example of a non-ionic polishing agent is hydrated alumina. This substance is usually in the form of small particles, with at least 85% of the particles being less than 20 gm, this material is usually classified as α-alumina trihydrate (gibbsite) and is usually given its chemical formula as Al ₂ O ₂ .3H ₂ O or Al (OH) 2. The mean particle size of this material is usually 6 to 9 μη. The particle size usually has the following distribution:

micrometers_ percent <30 94 - 99 <20 85 - 93 <10 56 - 67 <5 28-40

The polishing material is present in the composition in the form of a paste or gel, usually in an amount of 30% to 75% by weight.

Toothpastes or creams or gel cleansing compositions generally contain a natural or synthetic thickener or gel-forming agent in an amount of 0.1% to 10% by weight, preferably 0.5% to 5% by weight. A suitable thickener is, for example, an alkali metal complex magnesium silicate colloidal clay, which is available, for example, as Laponite (e.g., CP, SP 2002 or D, Laporte Industries Limited). Laponite D analysis gave a composition (in% by weight) of 58.00% SiO ₂ , 25.40% MgO, 3.05% Na ₂ O, 0.98% Li ₂ O 3 a small amount of water and a trace of metal. The density of this material is 2.53 g / cm @ 2 and the bulk density at a moisture content of 8% by weight is 1.0 g / ml.

l

Other suitable thickeners or gel formers are Irish moss, carrageenan, iota-carageenan, tragacanth rubber, starch, polyvinylpyrrolidone, hydroxyethylpropylcellulose, hydroxybutylmethylcellulose, hydroxypropylmethylcellulose (for example the product under the name Natrosol), the sodium carboxymethylcellulose in particular, colloidal silicon dioxide is also suitable, for example a product commercially marketed under the designation Syloid 244 or Sylodent 15.

In another aspect of the present invention, the oral composition is a mouthwash or a liquid dentifrice having a substantially liquid nature, in which case the vehicle used is typically a mixture of water and alcohol. The weight ratio of water to alcohol is usually in the range of 1: 1 to 20: 1, preferably in the range of 3: 1 to 10: 1, and in particular in the range of 4: 1 to 6: 1. these compositions range from 70% to 99.9% by weight. The alcohols used are non-toxic alcohol, for example ethanol or isopropanol. Glycerol or sorbitol may be used as humectants (or moisture stabilizers or solvents) in amounts ranging from 10% by weight to 30% by weight. Liquid dentifrice compositions typically comprise from about 50% to about 85% by weight of water, and may contain from about 0.5% to about 20% by weight non-toxic alcohol, as well as from about 10% to about 40% by weight humectant (moisture stabilizer or solvent) such as glycerol and / or sorbitol. In the case of sorbitol, this is a commercially available material in the form of a 7% or aqueous solution. The preferred non-toxic alcohol is ethanol. Alcohol is likely to help dissolve the water-insoluble non-cationic antibacterial, and it is believed that aromatic oil is likely to have the same effect.

As mentioned above, the non-cationic antibacterial is a substance that is substantially insoluble in water. However, in an oral composition of the invention containing AEA, such as, for example, a polycarboxylate that is in the form of an oral rinse or a liquid dentifrice, it is believed that the organic surfactant, flavoring oil or nontoxic alcohol helps to dissolve the antibacterial agent and thereby. they also make it easier to access the soft tissues of the oral cavity, particularly near or near the gingival margin and also to the tooth surface. The organic surfactants and / or flavoring oils may also be simultaneously co-solvents for dissolving the antibacterial agent, as well as any other ingredients present in the oral dentifrices.

To enhance the prophylactic effect, organic surfactants are also used in the compositions of the invention to assist in the complete dispersion of the anti-plaque antibacterial throughout the oral cavity, while also making the composition more cosmetically acceptable. The organic surfactant material is preferably of an anionic, nonionic or ampholytic nature, in which case it is preferred to use a wetting agent which simultaneously has a cleaning and foaming effect. Suitable examples of anionic surfactants are the water-soluble salts of higher aliphatic acids with monoglyceride monosulfates, for example sodium salts of monoglyceride monosulfates of hydrogenated coconut oil fatty acids, higher alkyl sulfates such as sodium lauryl sulfate, alkyl aryl sulfonates such as sodium dodecylbenzenesulfonate with 1,2-dihydroxypropanesulfonate and substantially saturated higher aliphatic acylamides derived from lower aliphatic aminocarboxylic acids, for example having 12 to 16 carbon atoms in the fatty acid, alkyl or acyl residue, and the like. Examples of such amides are N-lauroyl-sarcosine and the sodium or potassium salt of la-lauroyl-, N-myristoyl- or N-palmitoyl sarcosine, or a salt of these with ethanolamine, which should be substantially free of soaps or similar materials containing higher saturated aliphatic acids. The use of these sarcosinate compounds is particularly advantageous, since these materials have a long-lasting and significant effect in inhibiting oral acid formation in carbohydrate disintegration and further reduce the solubility of enamel in acidic solutions. Examples of water-soluble nonionic surfactants are the condensation products of ethylene oxide with various reactive hydrogen-containing compounds with a long hydrophobic chain, for example an aliphatic chain containing 12 to 12 carbon atoms. These condensation products (ethoxamers) contain hydrophilic polyoxyethylene moieties, for example polyethylene oxide condensation products with fatty acids, fatty alcohols, fatty amides, polyhydric alcohols such as sorbitan monostearate and polypropylene oxides (for example, the product available under the Pluronic designation) .

The surfactant is usually present in an amount of from about 0.5% to about 5% by weight, preferably from 1% to 25% by weight.

When the oral composition is in the form of a liquid dentifrice, it typically comprises a natural or synthetic thickener or gel-forming agent as defined above, in an amount ranging from about 0.1% by weight. % to about 10% by weight, preferably from 0.5% to 5% by weight.

Liquid dentifrices typically do not contain a polishing agent. However, as described in U.S. Patent No. 3,506,757 (Salzmann), these compositions may contain a polishing agent, said composition comprising from 0.3% to 2.0% by weight of a polysaccharide with a molecular weight greater than 1 000 000 containing mannose groups, glucose groups, potassium glucuronate groups and acetyl groups in an approximate ratio of 2: 1: 1: 1 as a suspending and thickening agent, and optionally containing from 10% to 20% by weight of a polishing material, such as hydrated aluminum oxide, calcium hydrogen phosphate dihydrate, calcium pyrophosphate, insoluble sodium metaphosphate, anhydrous calcium phosphate, calcium carbonate, magnesium carbonate, magnesium oxide, silicon dioxide or mixtures thereof.

Without being bound by theory, it is likely that the aqueous vehicle (humectant or humectant) will normally dissolve in micelles of the surfactant material in the mobile phase (i.e., the phase that does not include a gelling agent and a polishing agent, if present in dental

H- and detergent). This mobile phase-forming solution can be diluted with saliva in use to precipitate triclosan. That is, even in the absence of a specific solubilizer material for triclosan, with a total triclosan content in the range of 0.25% to 0.35% by weight and an AEA such as polycarboxylate, sufficient triclosan is present to provide an excellent anti-coating effect. on soft tissues and on the edge of the gum. The same applies to the other water-insoluble non-cationic antibacterial agents mentioned above.

The oral composition may also contain a fluoride ion source or fluorine-releasing component as an anti-caries agent in an amount sufficient to deliver about 25 ppm to about 5,000 ppm of fluoride ions. These substances are characterized by their ability to release fluoride ions into water and are not intended to have a substantial adverse effect on the action of the other components of the composition. These include, for example, inorganic fluorides, for example, soluble alkali metal and alkaline earth metal salts such as sodium fluoride, potassium fluoride, ammonium fluoride, calcium fluoride, copper fluoride, such as copper fluoride, zinc fluoride, barium fluoride, sodium fluorosilicate or ammonium fluorosilicate, sodium fluorosilicate or ammonium fluorosilicate, sodium monofluorophosphate, aluminum mono- and di-fluorophosphate and calcium pyrophosphate. Alkali and tin fluorides such as sodium and stannous fluoride, sodium monofluorophosphate (MFP) and mixtures thereof are most preferred.

The amount of the fluorine-providing compound depends to some extent on the type of compound, its solubility, and the type of final oral composition, but it must be a non-toxic amount, typically from about 0.0005% to about 3.0% by weight. % by weight. In a dentifrice composition, such as a dental gel, an amount of said substance that releases about 5,000 ppm of fluoride ion based on the weight of the composition is acceptable. Any minimum amount may be used in the present case, but it is preferred to use about 300 to about 2000 ppm, preferably 800 to 1500 ppm of fluoride ion.

In the case of alkali metal fluorides, this component is usually present in an amount of up to about 2% by weight based on the total composition, preferably in an amount ranging from about 0.05% to about 1% by weight. In the case of sodium monofluorophosphate, it may be present in an amount ranging from about 0.1% to about 3% by weight, preferably 0.76% by weight.

It will be understood that the composition for oral administration will be sold or otherwise distributed, as is usual, in a suitably labeled package. For example, a dentifrice gel will usually be contained in a compressible tube, usually of aluminum, coated or plastic, or another container may be used to compress, exhaust or measure its contents, indicating which container will always indicate the means goes.

Other materials may be incorporated into the oral compositions, for example, bleaching agents, preservatives, silicones, chlorophyll compounds and / or substances,

- 4 J - derived from ammonia such as urea, ammonium hydrogen phosphate and mixtures thereof. These auxiliary components, when used, are incorporated into the composition in an amount that does not substantially adversely affect the desired properties and effects of the composition. Larger amounts of zinc, magnesium and other metal salts, which are usually soluble and which could form a complex with the active ingredient of the composition, should not be used.

Suitable flavoring or flavoring or sweetening agents may also be used. Examples of such flavoring agents include some essential oils, for example, peppermint, peppermint, menthol, sassafras, clove, sage, eucalyptus, marjoram, cinnamon, lemon or orange or methyl salicylate. A suitable sweetener is, for example, sucrose, lactose, maltose, xylitol, sodium cyclamate, perillartin, AMP (asparylalanine methyl ester), saccharin and the like. Flavorants and sweeteners, individually or together, may comprise from about 0.1% to about 5% by weight of the composition. As is the case with surfactants, essential oils are likely to aid in the dissolution of the antibacterial agent with or in the absence of the surfactant.

The preferred composition of the invention for oral administration is preferably applied regularly to the enamel and soft tissues of the oral cavity, particularly at and near the gum line, for example every day or every other day or every third day, preferably 1 to 3 times a day at about pH 4. 5 to about 9 or 10, usually about 5.5 to about 8, preferably about 6 to about 8, and especially about 6.5 to about 7.5, for at least two weeks to 8 weeks or longer for life. Even at a low pH of about 5 or even lower, there is no decalcification or other breakdown of the enamel. The pH can be controlled with an acid such as citric or benzoic or a base (such as sodium hydroxide) or a buffer containing sodium citrate, benzoate, sodium carbonate or bicarbonate, sodium hydrogen phosphate, sodium dihydrogen phosphate and the like,

The composition according to the invention may be incorporated in the form of lozenges for sublingual use in chewing gum or other similar products, for example by mixing it into a warm rubber base or by applying it to the outer surface of the chewing gum, for which purpose jelutong may be used. , rubber latex, vinyl resin and the like, preferably these are used together with conventional plasticizers or plasticizers, sugar or other sweeteners or carbohydrates such as glucose, sorbitol and the like.

DETAILED DESCRIPTION OF THE INVENTION

The dental plaque composition for oral administration will be described in more detail below with reference to the following specific embodiments given in the examples, which are illustrative only and not limiting. All proportions and amounts indicated in the Examples are by weight unless otherwise indicated.

Example 1

In this example, a dentifrice composition having the following composition was prepared:

parts weight component AND (B)

glycerol 10.00 - propylene glycol - 10.00 sorbitol (70%) 25,00 25,00 iota carragenan 0.60 0.60 Gantrez S-97 2.00 2.00 saccharin sodium 0.40 0.40 sodium fluoride 0.243 0.243 sodium hydroxide (50%) 1.00 1.00 titanium dioxide 0.50 0.50 silica polishing agent (Zeodent 113) 20,00 20,00 silicone thickener (Sylox 14) 5.50 5.50 sodium lauryl sulphate 2.00 2.00 water 31,507 31,507 Triclosan 0.30 0.30 flavoring oil (essential oil) 0.95 0.95

a copolymer of methyl vinyl ether and maleic anhydride with a molecular weight of 70 000.

The aforementioned dentifrice A releases tricosan by the teeth and on the soft gum tissue substantially as well as the dentifrice B containing a special solubilizing agent for triclosan. Accordingly, there is no need to use a particular solubilizing agent to achieve adequate performance of the composition of the invention. The corresponding formulation, in which the polycarboxylate (Gantrez) was omitted, released tricosan much more poorly.

In this example, very good results can be obtained even if tricosan is replaced by another antibacterial as described above, such as phenol, thymol, eugenol and 2,2-methylenebis (4-chloro-6-bromophenol) and / or by replacing the methyl vinyl ether / maleic anhydride copolymer (Gantrez product) with another AEA type, such as a 1: 1 maleic anhydride / ethyl acrylate polymer, with a sulfoacrylate oligomer, some of the Carbopol compositions, which are essentially carboxyvinyl polymers, polyacrylic acid polymers cross-linked with polyallyl sucrose or polyallylpentaerythritol (for example, the product numbered 934), and polymers of α- or β-styrene-phosphonic acid monomers and copolymers thereof or copolymers thereof with other ethylenically unsaturated polymerizable monomers such as vinylphosphonic acid.

Example 2

The following liquid phase dental cleanser solutions were tested for saline-coated HA tricosan feed and retention in a manner similar to Example 1. The composition of the composition is shown in the following table, in the following table. the test result is shown.

component AND parts by weight BC D

Sorbitol (70%) 30.0 30.0 30.0 30.0 glycerol 9.5 9.5 9.5 9.5 propylene glycol 0.5 0.5 0.5 0.5 SLS 20.0 20.0 20.0 20.0 NaF 0.243 0.243 0.243 0.243 triclosan 0.3 0.3 0.3 0.3 with ilice 0.95 0.95 0.95 0.95 water 56,507 56,507 56,507 56,507

component AND parts by weight D (B) C poly- (β-styrene-phosphonic) 2,0 poly- (and -styrene-phosphonic) 2,0 polyvinyl alcohol 2,0

-τ υ

All formulations were adjusted to pH 6.5 by addition of sodium hydroxide.

AND (B) C D supply of triclosan in gg discs, coated saliva 31.0 174.0 86.0 36.0 retention of triclosan on HA wheels, coated saliva at the beginning of the test 183.0 after 30 minutes 136.0 after 1 hour 105.0 after 3 hours 83.0

The above results show that solution D, which contained polyvinyl alcohol not covered by the term AEA, provided a triclosan feed of only 36.0 μπι, similarly to control solution A completely free of additive for which a value of 31.0 μιπ is appropriate. In contrast, solution C, which contains poles (α-styrene-phosphonic acid), provides a feed rate of 86.0 μιπ, which is more than double that of solutions A and D, and solution B containing poles (β-styrene-phosphonic acid) provides approximately five times the feed Compared to solutions A and D, it is therefore clear that the multiple substitution of the antibacterial delivery promoting group provides very good results in this regard. The results also show surprisingly good triclosan retention on HA discs with solution B, which contained poles (β-styrenophosphonic acid) with a molecular weight ranging from 3,000 to 10,000.

Example 3

The effect of synthetic anionic linear polycarboxylates on the delivery, retention and release of water-insoluble non-cationic antibacterial agents from the tooth surface was tested in vitro on saliva-coated hydroxyapatite disks and isolated facial mucosal epithelial cells. The results obtained in vitro are comparable to similar in vivo values.

To test the delivery of the antibacterial agent to the saliva-coated hydroxyapatite disks, hydroxyapatite (HA), obtained from Monsato Co., was used, which was thoroughly washed with distilled water, filtered in vacuo and then was. dried overnight at 37 ° C The dried hydroxyapatite was ground to a powder in a mortar. Then, 150 milligrams of HA was placed in a chamber for production of potassium bromide pellets (Barnes Anylytical, Stanford, CT) and the material was compressed for 6 minutes at a pressure of approximately 5,000 kg in a laboratory press (Carver Laboratory). The resulting 13 mm diameter discs were sintered at 800 ° C in a furnace (Thermolyne) for 4 hours. Saliva was collected in an ice-cooled glass vial and clarified by centrifugation for 15 minutes at 15,000 x g at 4 ° C. They were then sterilized at the same temperature of 4 ° C and under stirring by irradiating the sample with ultraviolet light for 1 hour.

Each sintered disc was hydrated with sterile water in a polyethylene test tube. The water was then removed and replaced with 2.00 ml of saliva. Incubation of the disc overnight at 37 ° C and continuous shaking in a water bath created a saliva coating. The saliva was then removed and the discs were placed in a 1.0 ml solution containing antibacterial (Triclosan) for a dental liquid cleaner, and then the discs were incubated at 37 ° C with stirring in a water bath. After 30 minutes, the discs were transferred to a new tube, 5 ml of water was added and the disc was gently shaken (Vortex). The disc was then transferred to a new tube and the wash was repeated two more times. Finally, the disc was carefully transferred to a new tube so that no liquid was transferred. Then 1 ml of methanol was added to the plate and the plate was vigorously shaken (Vortex). The sample was then left at room temperature for 30 minutes to extract the absorbed triclosan into methanol. The methanol was then aspirated and clarified by centrifugation for 5 minutes in a microcentrifuge (Backman Microfuge 11) at 10,000 rpm. Then methanol was transferred to high pressure liquid chromatography vials to determine the antibacterial content. Each assay in all experiments was performed in triplicate.

In the saliva-coated HA disc retention test, the discs were contacted with a dentifrice suspension as described above. After incubation for 30 minutes at 37 ° C, the plates were removed, washed twice with water and then incubated again using saliva stimulated paraffilm after clarification by centrifugation. After incubation at 0 ° C with shaking, the disks were removed and the amount of antibacterial (triclosan) that was retained on the disks and then released into the saliva was determined using high pressure liquid chromatography.

In the test for release and delivery of the antibacterial to epithelial cells of the mucosa of the face, the effect of PVM / MA on the delivery of the antibacterial (triclosan) to the soft tissues of the oral cavity from the dentifrice was measured. Cells from the mucosa of the face were separated by a wooden stick, which was carefully wiped off the oral mucosa. Cells were suspended in a buffer containing salts usually present in saliva (RSS buffer) containing 50 nM NaCl, 1.1 nM CaCl ₂ and 0.6 nM KH ₂ PO ₄ (pH 7.0), for each the assay was used at 5-6 x 10 &lt; 6 &gt; cells / ml using a hemocytometer to count cells that were kept on ice until use. Then, 0.5 ml of the cell suspension previously incubated at 37 ° C in a water bath was added, along with 0.5 ml of the antibacterial test solution, and the mixture was incubated at 37 ° C. The antibacterial solution (triclosan) was diluted 10-fold in the incubation mixture to reduce the surfactant concentration and prevent cell membrane destruction by the agent. After 30 minutes of incubation, the cells were separated by centrifugation for 5 minutes at 5,000 rpm in a microfuge of the same type as above. The pellet-removed cells were washed three times with RSS buffer and then 1.5 ml of methanol was added. The sample was mixed thoroughly and then analyzed for antibacterial content by high pressure liquid chromatography.

In addition, dentifrices containing the individual ingredients listed in the following table were prepared:

component parts weight AND (B)

propylene glycol (1,2) 10.00 10.00 jota karrageenan 0.75 0.75 Gantrez S-97 - 2.00 titanium dioxide 0.50 0.50 Sorbitol (70%) 30,00 30,00 sodium fluoride 0.332 0.332 saccharin sodium 0.40 0.40

silicate thickener

Sylodent 15 3.00 3.00 silicate polishing substance (Zeodent 113) 20,00 20,00 Triclosan 0.20 0.20 sodium lauryl sulfate 2.00 2.00 essential oil 0.95 0.95 ethyl alcohol 1.00 1.00 water to 100.00 100.00

* methyl vinyl ether-maleic anhydride copolymer of 70,000 molecular weight.

The supply of triclosan to the hydroxyapatite disc, coated with saliva and epithelial cells of the mucosa of the face in the presence and absence of Gantrez S-97 polymeric polycarboxylate is summarized in Table 1 below.

TABLE 1

means triclosan intake in μ§ to discs with a saliva coating x 10 cells mucous membrane of the face AND 25.0 38.0 (B) 54.0 96.0

From these results, it is apparent that the Gantrez formulation of formulation B greatly enhances the delivery and delivery of triclosan to the hydroxyapatite disks as well as to the facial mucosal cells.

Similar results were obtained with 0.30 parts by weight of triclosan.

Example 4

Saliva-coated hydroxyapatite discs and separate facial mucosal cells other than those of Example 1 were tested using formulation B containing 2.00% by weight of Gantrez S-97 (i.e. a copolymer of methyl vinyl ether and maleic anhydride having a molecular weight of 70,000), 0.20% by weight of triclosan, 10.00% by weight of propylene glycol and 2.00% by weight of sodium lauryl sulfate, and an equivalent composition B &apos; 0.30% by weight, compared to a commercially available composition C containing hydrated alumina as a polishing agent and (a) 0.2% triclosan, (b) no Gantrez, (c) no propylene glycol, (d) 0,5% by weight of zinc citrate, (e) 2,5% by weight of surfactant, ( (f) sodium monofluorophosphate and hydrated alumina as a polishing agent, and was further used to compare composition C 'the same as composition C, except for the triclosan content, which in this case was 0.30% by weight. The composition of C 'is shown in the table.

Resource C '

component % by weight Sorbitol (70%) 27,00 sodium carboxymethylcellulose 0.80 sodium monofluorophosphate 0.85 zinc citrate 0.50 saccharin sodium 0.18 water 16.47 hydrated polishing agent aluminum oxide 50.00 ethanol 0.20 sodium lauryl sulphate 1,875 sodium dodecylbenzenesulfonate 0.625 triclosan 0.30 flavorings 1.20

Since compositions C and C ´ contain a total of 2.50% by weight of surfactant, a greater amount of this agent is available for dissolving triclosan than in compositions B and Β which contain 2.00% by weight of the surfactant. However, propylene glycol, which is included in the silica polishing agent (but not contained in the hydrated alumina polishing agent in compositions C and C '), ensures optimal dissolution of the triclosan.

Thus, the advantage of formulations B and B 'containing propylene glycol and Gantrez as compared to formulations C and C' consists in an improved supply of triclosan to both saliva-coated hydroxyapatite disks and isolated facial mucosal cells as shown in Table 2.

TABLE 2

p resources triclosan feed in gg on HA x 10 6 cells with a saliva coating of the mucous membrane of the face (B) 41.1 101.6 B ’ 77.4 142.0 C 20.4 61.0 C' 42.6 100.0

Further experiments with composition B '(containing 0.3% by weight of triclosan, Gantrez, ie a methyl vinyl ether-maleic anhydride copolymer and propylene glycol) in 50% dentifrice suspensions were performed to determine triclosan retention on saliva-coated hydroxyapatite discs during In these experiments, very advantageous values for triclosan were shown, as shown in Table 3.

TABLE 3

Retention cleaning adsorbed of teeth triclosan a suspension of the composition pr, time ( (minutes) retention triclosan (pg / disc)

0 70 30 60 60 70 120 65 180 57 240 59

These results demonstrate that dentifrices containing triclosan, Gantrez type, and propylene glycol provide improved delivery and retention of triclosan on the tooth surface and on the soft surface of the oral cavity, thereby providing improved anti-plaque and antibacterial effect.

Example 5

In this example, two formulations a and b were prepared for comparison with each other.

component % content by weight and b glycerol 10.00 propylene glycol - 10.00 jota carrageenan 0.60 0.60 Sorbitol (70%) 25,00 25,00 saccharin sodium 0.40 0.40 sodium fluoride 0.243 0.243 titanium dioxide 0.50 0.50 Gantrez S-97 2.00 2.00 water 29,157 29,157 sodium hydroxide (50%) 2.00 2.00 silicate polishing agent (Zeodent 113) 20,00 20,00 silicate thickener Sylodent 15 5.50 5.50 flavoring substance 1.10 1.10 triclosan 0.50 0.50 sodium lauryl sulphate 2.00 2.00 ethanol 1.00 1.00

a copolymer of methyl vinyl ether and maleic anhydride with a molecular weight of 70 000.

Composition A is a dentifrice composition comprising a Gantrez polycarboxylate-based composition, 0.5% by weight triclosan as an antibacterial, and no solubilizing agent. Composition b, which is otherwise of the same composition, contains propylene glycol as a solubilizing agent.

Upon testing of these compositions, it was found that composition a did not provide a sufficient supply of triclosan, while composition b provided a good supply of triclosan to the oral mucosa cells.

Thus, it is clear that all of these results confirm an excellent supply of triclosan from dentifrices.

Example 6

Experiments were performed with a group of volunteers to determine the effect of certain dentifrices on affecting re-formation of the dental plaque using the method described by Addy, Wilis and Moran, J. Clin. Perio, 1983, Vol. 10, pp. 89-99. The formulations tested included a control placebo (i) free of triclosan and a dentifrice of the invention (ii) containing 0.3 wt% triclosan, 10 wt% propylene glycol (instead of 3 wt% polyethylene glycols 600), and 2% by weight of Gantrez S-97, wherein the humectant (or solvent) contained propylene glycol and sorbitol. The composition is shown in the following table.

Ingredient content in% by weight

(and) (ii) polyethylene glycol 600 3.00 glycerol 25,00 - propylene glycol - 10.00 Sorbitol (70%) 41,617 25,00 sodium carboxymethylcellulose 0.35 - jota karrageeenan - 0.60 sodium benzoate 0.50 - saccharin sodium 0.20 0.40 sodium fluoride 0.243 0.243 silica polishing agent (Zeodent 113) 18.00 20,00 silicate thickener (Sylox 14) 5.50 5.50 water 3.00 28,757 Gantrez S-97 - 2.00 tríclosan - 0.30 titanium dioxide 0.50 0.50 sodium lauryl sulphate 1.20 2.50 flavoring substance 0.89 1.10 ethyl alcohol - 1.00 sodium hydroxide (50%) - 2.00

a copolymer of methyl vinyl ether and maleic anhydride with a molecular weight of 70 000.

Regarding the reduction of dental plaque formation on volunteer teeth, a statistically significant 20% reduction in plaque formation compared to the effect of composition (i) was shown for composition (ii) of the invention.

Since the content of 0.3% by weight of triclosan in toothpaste (ii) can be dissolved by a smaller amount of propylene glycol, similar results are expected if the propylene glycol content is reduced to 0.5% by weight and the amount of sorbitol is increased to 39.5% by weight. In the same manner, other solubilizing agents may be used instead of propylene glycol, such as dipropylene glycol, hexylene glycol, methylcellosolv, ethylcellosolv, olive oil, castor oil, petrolatum amyl acetate, ethyl acetate, glyceryl tristearate and benzyl benzoate to efficiently deliver triclosan to the oral tissues. Similar results are also expected when propylene glycol or other solubilizing agent is not used in the toothpaste composition (ii) containing 0.3% by weight of triclosan.

Example 7

According to this example, further dentifrice compositions of the present invention have been prepared, the composition of which is shown in the following table;

component parts AND weight (B) glycerol 20,00 propylene glycol 10.00 0.50 Sorbitol (70%) 25,00 19.50 sodium carboxymethylcellulose - 1.10 jota carrageenan 0.60 - saccharin sodium 0.40 0.30 sodium fluoride 0.243 0.243 silica polishing agent (Zeodent 113) 20,00 20,00 silicate thickener (Sylox) 5.50 3.00 water 28,757 28,757 Gantrez S-97 2.00 2.00 triclosan 0.50 0.30 titanium dioxide 0.50 0.50 sodium lauryl sulphate 2.50 2.00 flavoring 1.10 0.95 ethanol 1.00 - sodium hydroxide (50%) 2.00 1.60

* a copolymer of methyl vinyl ether and maleic anhydrides with a molecular weight of 70,000.

In the previous examples, similar results can also be obtained when triclosan is replaced by another antibacterial such as phenol, thymol, eugenol and 2,2-methylenebis- (4-chloro-6-bromophenol), or by replacing Gantrez with another type of AEA, such as a 1: 1 ratio of maleic anhydride / ethyl acrylate copolymer, sulfoacrylic acid oligomers, one of Carbopol. (which are substantially colloidal water-soluble polyacrylic acid polymers crosslinked by the addition of 0.75% to about 2.0% polyallylsaccharose or polyallylpentaerythritol), such as Carbopol 934, polymers of monomeric or beta-styrene phosphonic acids and copolymers of these styrenephosphonic acid monomers or copolymers with another ethylenically unsaturated polymerizable monomer, for example, in vinyl phosphonic acid.

Example 8

In this example, dentifrices having the following composition were prepared:

component parts by weight A B C

α-alumina trihydrate 48,00 48,00 48,00 propylene glycol - 0.50 0.50 Sorbitol (70%) 21.70 21.70 21.70 Gantrez S-97 * (13% solution) 15.00 15.00 - Gantrez S-97 (powder) - - 2.00 sodium lauryl sulfate 2.00 2.13 2.13 saccharin sodium 0.30 0.30 0.30 sodium hydroxide (50%) 1.20 1.20 1.20 flavoring substance 0.95 0.95 0.95 karagen 1.00 - - sodium carboxymethylcellulose - 1.00 1.00 sodium monofluorophosphate 0.76 0.76 0.76 titanium dioxide - 0.50 0.50 triclosan 0.30 0.30 0.30 water to 100.00 100.00 100.00

* methyl vinyl ether-maleic anhydride copolymer of 70,000 molecular weight.

All said dentifrices provide substantially better delivery of triclosan to the tooth surface and to the soft tissue surface of the oral cavity than corresponding dentifrices not containing Gantrez polycarboxylate-based compositions.

Example 9

In this example, dentifrices having the following composition were prepared:

component parts weight glycerol 22,00 10.00 Sorbitol (70%) - 17.00 sodium carboxymethylcellulose 1.00 1.00 Gantrez S-97 2.00 2.00 saccharin sodium 0.20 0.20 sodium benzoate 0.50 0.50 sodium monofluorophosphate 0.76 0.76 dibasic phosphate dihydrate calcium 48.76 48.76 triclosan 0.30 0.30 sodium lauryl sulphate 1.20 1.20 flavoring substance 0.89 0.89 water to 100.00 100.00

* a copolymer of methyl vinyl ether and maleic anhydride with a molecular weight of 70,000.

Both of the aforementioned dentifrices provide far better delivery of triclosan to the saliva-coated hydroxyapatite discs than the corresponding dentifrices which do not contain a polycarboxylate-type Gantrez.

Example 10

A dentifrice having anti-tartar activity can be prepared from the following ingredients:

component parts by weight glycerol 15.00 propylene glycol 2.00 sodium carboxymethylcellulose 1.50 water 24.93 a copolymer of vinyl methyl ether and anhydride maleic acid (42% solution) 4.76 sodium monofluorophosphate 0.76 carbohydrate sodium 0.30 insoluble sodium metaphosphate 47,00 titanium dioxide 0.50 sodium lauryl sulphate 2.00 triclosan 0.30 flavoring substance 0.95

In the previous examples, improved results may also be obtained when triclosan is replaced by phenol, 2,2'-methylene-bis (4-chloro-6-bromophenol), eugenol or thymol and / or Gantrez is replaced by another type of AEA such as is, for example, Carbopol (which are substantially colloidal water-soluble polyacrylic acid polymers crosslinked by the addition of 0.75% to about 2.0% polyallylsaccharose or polyallylpentaerythritol), for example, the product labeled

934, or polymers of styrene phosphonic acid having a molecular weight in the range of about 3,000 to 10,000, such as β-styrene phosphonic acid polymer, vinylphosphonic acid-β-styrene phosphonic acid copolymers and α-styrene phosphonic acid polymers, sulfoacrylic acid oligomers or acid anhydride copolymers maleic acid with ethyl acrylate in a ratio of 1: 1.

Example 11

In this example, the mobile phases of the triclosan-containing dentifrice were prepared, the total composition of which is shown in the following table:

component % content by weight AND (B) Sorbitol (70%) 53.33 40.00 water 40.48 39.15 Gantrez S (15%) - 13.33 sodium hydroxide (50%) - 1.33 saccharin 0.40 0.40 sodium fluoride 0.32 0.32 flavoring substance 1.47 1.47 sodium lauryl sulphate 3.33 3.33 triclosan 0.67 0.67

* synthetic anionic polycarboxylate-based product

The concentration of the above ingredients in the dentifrice was 1.33% by weight, moreover, the dentifrice composition contained up to 25% by weight of the abrasive material required to replenish the detergent composition.

Said mobile phases were tested for triclosan feed and retention on saliva-coated HA discs. The results are shown in the following table.

TABLE

Triclosan feed to the saliva-coated HA disk from the diluted and undiluted mobile phase of the detergent

AND (B) % by weight of triclosan 0.67 0.67 calculated ionic strength (M / L) 0.375 - pH 8.7 7.6 intake of undiluted triclosan (pg / disk) 55 122

The above results show a more than two-fold increase in the triclosan intake of formulation B containing Gantrez compared to the effect of formulation A without Gantrez.

Example 12

The feed of triclosan to HA disks from a 1: 1 dentifrice suspension supernatant was investigated, the dentifrice containing 0.5% by weight triclosan and 2.5% by weight sodium lauryl sulfate. The other ingredients are listed in the table as well as the results obtained:

next folder triclosan content feed dental cleansing in the supernatant triclosan means suspension 1: 1 (gg / ml (pg / disk)

25% by weight hydrated S1O2 + 1.5% Gantrez * 1,650 52 50% by weight of oxide aluminum + 1,5% weight Gantrez * 1,905 74

* synthetic anionic product based on polycarboxylates

Supernatants of the above-mentioned 1: 1 detergent / water slurry were examined for triclosan concentration and its delivery to saliva-coated HA disks. The results show that when 50% alumina is used as an abrasive, the triclosan concentration is greatly increased at a large dilution, i.e. from 1.650 to 1.905, and thus the triclosan feed is also increased from 52 to 74.

Example 13

Mouthwashes of the following composition were prepared that effectively reduced dental plaque formation by effectively increasing triclosan uptake and retention on the oral cavity surface.

component AND parts by weight B C D E

Gantrez S-97 0.24 0.25 0.25 0.25 0.25 glycerol 15.00 10.00 15.00 10.00 15.00 ethanoI - - 12.50 12.50 - propylene glycol - 5.00 - 5.00 - block copolymer polyoxyethylene; and polyoxypropylene Pluronic F108 - 2.00 - - - sodium lauryl sulphate - - 0.20 0.20 0.20 triclosan 0.10 0.10 0.06 0.06 0.03 flavoring substance 0.40 0.40 0.40 0.40 0.40 water to 100.00 100.00 100.00 100.00 100.00

a copolymer of methyl vinyl ether and maleic anhydride with a molecular weight of 70 000.

Example 14

The following liquid tooth cleansing compositions were prepared which also effectively reduced the formation of dental plaques by increasing the uptake and retention of triclosan on the oral cavity surface.

component parts AND weight: (B) and C glyce rol 20,00 20,00 Gantrez S-97 0.3 0.3 0.3 high molecular weight polysaccharide containing mannose, glucose, potassium glucuronate and of acetyl groups in approximate molar ratio of 2: 1: 1: 1 0.8 - 1.0 sodium benzoate 0.5 0.5 0.5 saccharin sodium 0.5 0.5 0.5 water 61.3 73.1 71.6 sodium lauryl sulphate 3.0 3.0 3.0 insoluble sodium metaphosphate 10.0 - 10.0 anhydrous hydrogen phosphate Calcium 1.0 - 2.5 flavoring substance 2.5 2.5 2.5 ethyl alcohol - - 10.0 triclosan 0, 1 0.1 0.1

* methyl vinyl ether / maleic anhydride copolymer of 70,000 molecular weight.

In the embodiments of the previous examples, improved results can also be obtained when triclosan is replaced by phenol, 2,2'-methylene-bis (4-chloro-6-bromophenol), eugenol or thymol, and / or when Gantrez is replaced by another type of AEA such as Carbopol product designation 934 (which is essentially a product consisting of a colloidal water-soluble polyacrylic acid polymer crosslinked by the addition of 0.75% to about 2.0% polyallylsaccharose or polyallylpentaerythritol as a crosslinking agent), or polymers of molecular weight styrene phosphonic acid in the range of 3,000 to 10,000, such as polymers of β-styrene phosphoric acid, copolymers of vinylphosphonic acid and β-styrene phosphonic acid, polymers of α-styrene phosphonic acid or oligomers of sulfoacrylic acid or copolymers of maleic anhydride with ethyl acrylate in a ratio of 1: 1,

The invention has been described in connection with several preferred embodiments, but it will be apparent that many modifications may be envisaged which are obviously intended to be encompassed within the scope of the invention and thus to form a part thereof. Thus, the invention is not limited to these embodiments.

Claims (35)

PATENT CLAIMS «ΛΛ> Τ VotTEÚXJI / Χ'ν - ' 12H Λ) PMžiA i An anti-dental plaque composition for oral administration in the form of a gel-like or pasty dentifrice, liquid dentifrice, mouthwash, lozenge or chewing gum substantially free of a pyrophosphate anti-tartar composition comprising an oral delivery vehicle. and 0.01 to 5% by weight of a substantially water-insoluble non-cationic antibacterial agent dissolved in said vehicle in an effective amount against dental plaque formation, wherein the vehicle also comprises from about 0.005% to about 4% by weight of the antibacterial agent. an average molecular weight of 100 to 1,000,000, which comprises at least one acidic functional group with a release-enhancing effect to promote release of said antibacterial agent on the surfaces of teeth and gums in the oral cavity and at least one organic group of the formula; -O (X) _n -R wherein: X is oxygen, nitrogen, sulfur, SO, SO2, phosphorus, PO or silicon; R is a hydrophobic alkyl, alkylene, acyl, aryl, alkaryl and aralkyl group containing 1 to 12 carbon atoms , or an inert substituted derivative thereof, when n is 1 or zero, with a retention aid for promoting retention of said antibacterial agent on the tooth and gum surfaces in the oral cavity, wherein the AEA comprises natural and synthetic polymerizable monomers, oligomers, homopolymers, copolymers consisting of two or multiple monomers, ionomers, block copolymers, graft copolymers or crosslinked copolymers or monomers containing styrene phosphonic acid polymers, phosphonated polymerized ethylenically unsaturated compounds, polymerized ethylenically unsaturated carboxylic acids, carboxyvinyl polymers, polysiloxanes, polyesters, polyurethane ethanes, natural or synthetic polyamides, Composition for oral administration according to claim 1, characterized in that it optionally further comprises dissolving agents and / or polishing agents. The composition for oral administration of claim 1, wherein the composition is in the form of a dentifrice and comprises 5 to 30% by weight of a silica or aluminate silicate polishing agent, and said antibacterial agent is present in an amount ranging from 0.25 to 0.35% by weight, further comprising a surfactant and a flavoring oil. A composition for oral administration according to claim 1, wherein the composition is in the form of a dentifrice and comprises 5 to 30% by weight of a silica or aluminum silicate polishing agent, said antibacterial agent being present in an amount of from 0 to 5%. The composition for oral administration comprises a solubilizing agent for dissolving said antibacterial agent in saliva. The composition for oral administration of claim 4, wherein said antibacterial agent is present in an amount of from 0.05% to 0.25% by weight. The composition for oral administration of claim 4, wherein said antibacterial agent is present in an amount of from 0.35% to 5% by weight. The composition for oral administration of claim 6, wherein said antibacterial agent is present in an amount of from 0.35% to 0.5% by weight. The oral composition of claim 1, wherein the oral composition is in the form of a creamy dentifrice composition containing from 30 to 75% by weight of a water-insoluble dental acceptable polishing composition. The composition for oral administration of claim 1, wherein the composition is in the form of a mouthwash or a liquid dentifrice, and said orally acceptable vehicle is an aqueous vehicle that comprises at least one surfactant, flavoring oil or non-toxic alcohol. The oral dentifrice composition of claim 1, wherein the surfactant is present in an amount ranging from 0.5 to 5% by weight. A composition for oral administration in the form of a dentifrice composition according to claim 1 or 10, characterized in that it contains flavoring oil in an amount ranging from 0.1 to 5% by weight. A composition for oral administration according to claim 9, wherein the composition is in the form of a mouthwash and said aqueous vehicle comprises ethanol and the weight ratio of water to ethanol ranges from 1: 1 to 20: 1. A composition for oral administration according to claim 9, wherein the composition is in the form of a liquid dentifrice containing from 0.3 to 2.0% by weight of a high molecular weight polysaccharide of greater than 1,000,000 containing mannose, glucose. , a potassium glucuronate and an acetyl group in a ratio of 2: 1: 1: 1 as a suspending and thickening agent, and 10 to 20% by weight of a polishing agent. The composition for oral administration of claim 1, wherein said antibacterial agent is selected from the group consisting of halogenated diphenyl ethers, halogenated salicylanilides, benzoic acid esters, halogenated carbanilides, and phenolic compounds. The composition for oral administration of claim 14, wherein said antibacterial agent is a halogenated diphenyl ether. The composition for oral administration of claim 15, wherein said halogenated di-phenyl ether is 2,4,4'-trichloro-2'-hydroxyphenyl ether. A composition for oral administration according to claim 2, wherein said solubilizer is present in an amount ranging from 0.5 to 50% by weight, selected from the group consisting of propylene glycol, dipropylene glycol, hexylene glycol, methylcellosol, ethylcellosol, vegetable. oils and waxes containing at least 12 carbon atoms, amyl acetate, ethyl acetate, glyceryl tristearate and benzyl benzoate. The oral composition of claim 17 in the form of a dentifrice composition, wherein said solubilizer comprises propylene glycol present in an amount of 0.5% by weight. A composition for oral administration according to claim 1 or 17, comprising a polishing agent selected from the group consisting of sodium metaphosphate, calcium phosphate, dibasic calcium phosphate dihydrate, dibasic calcium phosphate, calcium pyrophosphate, magnesium orthophosphate, magnesium phosphate, calcium carbonate, aluminum silicate, hydrated alumina, silica, bentonite and mixtures thereof, and this oral composition is in the form of a cream dentifrice. The oral dentifrice composition of claim 19, wherein said polishing agent is dicalcium phosphate dihydrate or hydrated alumina. 21. A composition according to claim 1, wherein said release-promoting group is selected from the group consisting of carboxylic acids, phosphonic acids, phosphinic acids, and sulfonic acids, and salts thereof, and mixtures thereof. The composition for oral administration of claim 1, wherein said antibacterial enhancer is an anionic polymer comprising a plurality of release-promoting and retention-promoting groups. A composition for oral administration according to claim 22, wherein said anionic polymer comprises a chain comprising repeating units with at least one carbon atom, A composition for oral administration according to claim 23, wherein each unit comprises at least one release promoting group attached to the same atom, adjacent atom, or to another atom in the chain. The composition for oral administration of claim 21, wherein the release promoting group is a carboxyl group or a salt derived therefrom. The composition for oral administration of claim 25, wherein the antibacterial enhancing agent is a copolymer of maleic acid or anhydrides thereof with another inert ethylenically unsaturated polymerizable monomer. The composition for oral administration of claim 26, wherein said second monomer of said copolymer is methyl vinyl ether contained in a molar ratio ranging from 4: 1 to 1; 4 with respect to the amount of maleic acid or anhydrides thereof. The oral composition of claim 27, wherein said copolymer has a molecular weight in the range of from 30,000 to 1,000,000, and is present in an amount of from 0.1 to 2% by weight. The composition of claim 28, wherein said polymer has an average molecular weight of 70,000. 30. The composition of claim 21, wherein said release-enhancing group is a phosphonic acid or salt thereof. The composition of claim 30, wherein the antibacterial enhancing agent is a polymer of poly (beta-styrene phosphonic acid) or poly (alpha-styrene phosphonic acid), or a copolymer of any of said styrene phosphonic acids with another ethylenically unsaturated monomer. 32. A composition for oral administration according to claim 21, wherein said antibacterial promoting agent has an average molecular weight in the range of 1,000 to 1,000,000 and is substantially free of water-soluble alkali metal salts of synthetic anionic linear polymeric polycarboxylates. or ammonia having a molecular weight in the range of 1000 to 1 000 000 The composition for oral administration of claim 32, wherein said antibacterial agent is present in an amount ranging from 0.25% to 0.5% by weight. 34. A composition for oral administration according to claim 32, wherein said antibacterial agent is present in an amount ranging from 0.25% to 0.35% by weight. The composition for oral administration of claim 33 or 34, wherein said composition comprises a polishing agent based on silica or aluminum silicate.